未找到相关数据
Phase 2 study of neoadjuvant dabrafenib plus trametinib (D plus T) for resectable stage iib/c BRAF-V600 mutation positive melanoma.
被引：6
作者：
Saw, Robyn
Menzies, Alexander M.
Guminski, Alexander
Nieweg, Omgo E.
Shannon, Kerwin F.
Gonzalez, Maria
Ch'ng, Sydney
Kefford, Richard
Thompson, John F.
Stretch, Jonathan
Spillane, Andrew J.
Scolyert, Richard A.
Long, Georgina V.
机构：
[1] Melanoma Inst Australia, North Sydney, Australia
[2] Univ Sydney, North Sydney, Australia
[3] Univ Sydney, Melanoma Inst Australia, Royal North Shore Hosp, North Sydney, Australia
[4] Melanoma Inst Australia, Sydney, NSW, Australia
[5] Antoni Leeuwenhoek Hosp, Netherlands Canc Inst, Amsterdam, Netherlands
[6] Melanoma Inst Australia, North Sydney, Australia
[7] Royal Prince Alfred Hosp, Inst Acad Surg, Camperdown, NSW, Australia
[8] Crown Princess Mary Canc Ctr, Sydney, NSW, Australia
[9] Univ Sydney, Melanoma Inst Australia, Royal Prince Alfred Hosp, Sydney, NSW, Australia
[10] Mater Hosp, Sydney, NSW, Australia
[11] Royal Prince Alfred Hosp, Sydney, NSW, Australia
[12] Univ Sydney, Melanoma Inst Australia, Royal Prince Alfred Hosp, Sydney, NSW, Australia
关键词：
D O I：
10.1200/JCO.2016.34.15_suppl.9583
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
9583
引用
收藏
页数：2
相关论文